Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB/c mice

Immunobiology

Volumn 218, Issue 12, 2013, Pages 1524-1528

  Hu, Xiaobo ^a   Liu, Rui ^a   Zhu, Naishuo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Adjuvant; MPLA; Rabies virus

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; PHOSPHORYL LIPID A; RABIES VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOPOTENTIATION; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABIES; T LYMPHOCYTE ACTIVATION; UPREGULATION; VACCINATION;

ADJUVANT; MPLA; RABIES VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; INTERLEUKIN-4; LIPID A; MICE; MICE, INBRED BALB C; RABIES; RABIES VACCINES; RABIES VIRUS;

EID: 84885921675     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2013.05.006     Document Type: Article

References (37)

1. Bakker A.B., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M.F., et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008, 26:5922.
2. Baldrick P., Richardson D., Elliott G., Wheeler A.W. Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant. Regul Toxicol Pharmacol 2002, 35:398.
3. Baldridge J.R., McGowan P., Evans J.T., Cluff C., Mossman S., Johnson D., et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004, 4:1129.
4. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 1999, 163:6448.
5. Charlton K.M., Casey G.A., Campbell J.B. Experimental rabies in skunks: immune response and salivary gland infection. Comp Immunol Microbiol Infect Dis 1987, 10:227.
6. De Becker G., Moulin V., Pajak B., Bruck C., Francotte M., Thiriart C., et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 2000, 12:807.
7. Didierlaurent A.M., Morel S., Lockman L., Giannini S.L., Bisteau M., Carlsen H., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186.
8. Ertl H.C. Novel vaccines to human rabies. PLoS Negl Trop Dis 2009, 3:e515.
9. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2:219.
10. Flemming A. Vaccines: nano-adjuvant: double TLR stimulation is the key. Nat Rev Drug Discov 2011, 10:258.
11. Garcon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011, 10:471.
12. Hemachudha T., Laothamatas J., Rupprecht C.E. Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges. Lancet Neurol 2002, 1:101.
13. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543.
14. Lahiri A., Das P., Chakravortty D. Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine 2008, 26:6777.
15. Lau Y.F., Tang L.H., McCall A.W., Ooi E.E., Subbarao K. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J Virol 2010, 84:8639.
16. Lau Y.F., Tang L.H., Ooi E.E. A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 2009, 27:1354.
17. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004, 82:497.
18. Liu Y., Zhang S., Zhang F., Hu R. Adjuvant activity of Chinese herbal polysaccharides in inactivated veterinary rabies vaccines. Int J Biol Macromol 2012, 50:598.
19. Lodmell D.L., Ray N.B., Ulrich J.T., Ewalt L.C. DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL). Vaccine 2000, 18:1059.
20. Manning S.E., Rupprecht C.E., Fishbein D., Hanlon C.A., Lumlertdacha B., Guerra M., et al. Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008, 57:1.
21. Moore A., McCarthy L., Mills K.H. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999, 17:2517.
22. Parker R.L., Wilsnack R.E. Pathogenesis of skunk rabies virus: quantitation in skunks and foxes. Am J Vet Res 1966, 27:33.
23. Ravindran R., Maji M., Ali N. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Mol Pharm 2012, 9:59.
24. Sen G.C., Sarkar S.N. Transcriptional signaling by double-stranded RNA: role of TLR3. Cytokine Growth Factor Rev 2005, 16:1.
25. Shen E., Li L., Li L., Feng L., Lu L., Yao Z., et al. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA. Cell Mol Immunol 2007, 4:113.
26. Smith J.S., Fishbein D.B., Rupprecht C.E., Clark K. Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med 1991, 324:205.
27. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997, 336:86.
28. Ten B.A., van Schijndel G., Visser R., de Gruijl T.D., Zwaginga J.J., van Ham S.M. Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential. Cancer Immunol Immunother 2010, 59:1185.
29. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998, 16:708.
30. Thompson B.S., Chilton P.M., Ward J.R., Evans J.T., Mitchell T.C. The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells. J Leukoc Biol 2005, 78:1273.
31. Thompson H.S., Davies M.L., Watts M.J., Mann A.E., Holding F.P., O'Neill T., et al. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A. Vaccine 1998, 16:1993.
32. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol 1995, 6:495.
33. Vernacchio L., Bernstein H., Pelton S., Allen C., MacDonald K., Dunn J., et al. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 2002, 20:3658.
34. Wang X., Bao M., Wan M., Wei H., Wang L., Yu H., et al. A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine 2008, 26:1893.
35. Yu J., Li H., Tang Q., Rayner S., Han N., Guo Z., et al. The spatial and temporal dynamics of rabies in China. PLoS Negl Trop Dis 2012, 6:e1640.
36. Zhang C., Gong L., Chen Y., Wang X., Zhu S., Li D., et al. A human-derived protein SBP (HBsAg-binding protein) can bind to hepatitis B virus surface antigen (HBsAg) and enhance the immune response to hepatitis B virus (HBV) vaccine. Mol Immunol 2013, 53:60.
37. Zhu Q., Egelston C., Gagnon S., Sui Y., Belyakov I.M., Klinman D.M., et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010, 120:607.